Related Experiment Video
Updated: Feb 24, 2026
Flow Cytometric Characterization of Murine B Cell Development
Published on: January 22, 2021
Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders
Gaurav Chatterjee1, Sumeet Gujral1, Papagudi G Subramanian1
1Hematopathology Laboratory, Tata Memorial Center, Room 17-18, CCE Building, ACTREC, Tata Memorial Center, Kharghar, Navi Mumbai, 410210 Maharashtra India.
Insights
Multicolor flow cytometry (MFC) is now a standardized and sensitive tool for diagnosing plasma cell disorders (PCD) and monitoring treatment response. Advances in MFC technology have overcome previous limitations, establishing its clinical relevance in managing multiple myeloma and related conditions.
Area of Science:
- Hematology
- Immunology
- Clinical Pathology
Background:
- Multicolor flow cytometry (MFC) is crucial for evaluating hematolymphoid malignancies.
- Historically, MFC use in plasma cell disorders (PCD) faced challenges due to standardization issues, limited experience, and lower sensitivity compared to morphology.
- Technological advancements and reagent availability have enabled standardized, sensitive MFC assays for PCD.
Purpose of the Study:
- To review the applications of MFC in the management of plasma cell disorders (PCD).
- To discuss the clinical relevance of MFC in diagnosing and risk-stratifying PCD.
- To highlight MFC's role in monitoring treatment response for PCD.
Main Methods:
- Review of recent studies and technological advancements in MFC for PCD.
- Establishment of standardized, sensitive MFC-based immunophenotypic assays.
- Evaluation of MFC's diagnostic and prognostic capabilities.
Main Results:
- MFC has demonstrated high clinical relevance in diagnosing and risk-stratifying multiple myeloma and other PCDs.
- Standardized MFC assays are now widely available globally.
- MFC is a sensitive and reliable technique for monitoring treatment response in the era of novel therapies.
Conclusions:
- MFC is an essential tool in the management of plasma cell disorders.
- MFC's sensitivity and standardization have improved significantly, overcoming previous limitations.
- MFC plays a vital role in diagnosis, risk stratification, and treatment monitoring for PCD.
Abstract:
Multicolor flow cytometric (MFC) immunophenotyping is one of the basic test that is needed in the evaluation of hematolymphoid malignancies. Previously, there has been some reluctance in the use of MFC in plasma cell disorders (PCD). It was mainly due tolack of standardization, inadequate experience and detection of the lower number of plasma cells by MFC as compared to morphology. However, MFC has gone through many technological advancements in the last few years and a wide variety of reagents are now commercially available which worldwide allowed the establishment of standardized sensitive MFC-based immunophenotypic assay for PCD. Various studies have proven that MFC has a high clinical relevance in the diagnosis and risk stratification of multiple myeloma, its precursor conditions and other PCDs. Moreover, recent studies have shown that MFC is a highly sensitive and reliable technique for the monitoring of clinical response in the era of novel therapies. In this review, we have discussed the various applications of MFC in the management of PCD and their clinical relevance.
